Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tafamidis

FDA-approved product (capsule, oral), marketed as Vyndamax, Vyndaqel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Tafamidis
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • AL amyloidosis
  • Amyloidosis
  • Cardiomyopathy

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other nervous system drugs
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tafamidis in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tafamidis with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fasting Conditions

    NCT07587697 · start 2026-05-11

    Registered record
    Registry ID
    NCT07587697
    Conditions
    Healthy Adults
    Interventions
    Tafamidis; Tafamidis; Tafamidis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2026-05-11
    Completion
    2026-08-03
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adults
    InterventionTafamidis; Tafamidis; Tafamidis
    PhasePhase 1
    Registry statusCompleted

  • A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fed Conditions

    NCT07470866 · start 2026-03-23

    Registered record
    Registry ID
    NCT07470866
    Conditions
    Healthy
    Interventions
    Tafamidis (Reference); Tafamidis (Test)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2026-03-23
    Completion
    2026-06-02
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTafamidis (Reference); Tafamidis (Test)
    PhasePhase 1
    Registry statusTerminated

  • Liver and Coagulation Disorders in Cardiac Transthyretin Amyloidosis

    NCT07766135 · start 2026-01-30

    Registered record
    Registry ID
    NCT07766135
    Conditions
    Transthyretin (TTR) Amyloid Cardiomyopathy; Cardiac Amyloidosis; Cardiomyopathies; Wild-Type Transthyretin Cardiac Amyloidosis; Hereditary Transthyretin Amyloidosis (ATTRv)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-01-30
    Completion
    2028-01
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin (TTR) Amyloid Cardiomyopathy; Cardiac Amyloidosis; Cardiomyopathies; Wild-Type Transthyretin Cardiac Amyloidosis +1 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study

    NCT07196839 · start 2025-12-31

    Registered record
    Registry ID
    NCT07196839
    Conditions
    Transthyretin (TTR) Amyloid Cardiomyopathy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-12-31
    Completion
    2027-03
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin (TTR) Amyloid Cardiomyopathy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy

    NCT06940336 · start 2025-06-19

    Registered record
    Registry ID
    NCT06940336
    Conditions
    Transthyretin Amyloid Polyneuropathy
    Interventions
    Tafamidis Meglumine Soft Capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-06-19
    Completion
    2028-02
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin Amyloid Polyneuropathy
    InterventionTafamidis Meglumine Soft Capsules
    PhasePhase 4
    Registry statusRecruiting

  • Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

    NCT06393465 · start 2024-06-15

    Registered record
    Registry ID
    NCT06393465
    Conditions
    Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
    Interventions
    Tafamidis
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-06-15
    Completion
    2026-04-07
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
    InterventionTafamidis
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India

    NCT06086353 · start 2024-03-25

    Registered record
    Registry ID
    NCT06086353
    Conditions
    Transthyretin Amyloid Cardiomyopathy
    Interventions
    Tafamidis
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-03-25
    Completion
    2025-06-06
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin Amyloid Cardiomyopathy
    InterventionTafamidis
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

    NCT06321523 · start 2024-03-19

    Registered record
    Registry ID
    NCT06321523
    Conditions
    Transthyretin Amyloid Cardiomyopathy
    Interventions
    Tafamidis 61 milligrams
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-03-19
    Completion
    2025-10-13
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin Amyloid Cardiomyopathy
    InterventionTafamidis 61 milligrams
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Learn How Different Forms of Study Medicine Tafamidis Are Taken Up Into The Blood in Healthy Adults

    NCT06273839 · start 2024-02-27

    Registered record
    Registry ID
    NCT06273839
    Conditions
    Healthy
    Interventions
    Tafamidis 61 mg free acid tablet (Test 1); Tafamidis 70 mg free acid tablet (Test 1); Tafamidis 61 mg free acid capsule (Reference)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-02-27
    Completion
    2024-05-27
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTafamidis 61 mg free acid tablet (Test 1); Tafamidis 70 mg free acid tablet (Test 1); Tafamidis 61 mg free acid capsule (Reference)
    PhasePhase 1
    Registry statusCompleted

  • NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis

    NCT06251778 · start 2024-01-26

    Registered record
    Registry ID
    NCT06251778
    Conditions
    Amyloidosis; Amyloidosis Cardiac; ATTR Amyloidosis Wild Type
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-01-26
    Completion
    2027-01-26
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyloidosis; Amyloidosis Cardiac; ATTR Amyloidosis Wild Type
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation

    NCT05489523 · start 2023-05-01

    Registered record
    Registry ID
    NCT05489523
    Conditions
    Transthyretin Cardiac Amyloidosis
    Interventions
    Tafamidis 61 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2023-05-01
    Completion
    2027-05-31
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTransthyretin Cardiac Amyloidosis
    InterventionTafamidis 61 MG
    PhasePhase 4
    Registry statusActive not recruiting

  • A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis

    NCT05139680 · start 2023-03-08

    Registered record
    Registry ID
    NCT05139680
    Conditions
    Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype
    Interventions
    tafamidis
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-03-08
    Completion
    2023-05-19
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype
    Interventiontafamidis
    PhaseNot recorded
    Registry statusCompleted

  • Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.

    NCT05560555 · start 2022-10-24

    Registered record
    Registry ID
    NCT05560555
    Conditions
    Hereditary Transthyretin Amyloidosis (ATTRv); Polyneuropathy
    Interventions
    Tafamidis
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2022-10-24
    Completion
    2022-11-15
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHereditary Transthyretin Amyloidosis (ATTRv); Polyneuropathy
    InterventionTafamidis
    PhaseNot recorded
    Registry statusCompleted

  • A Study Comparing Two Forms of Tafamidis Without Food and the Amount of Tafamidis in the Blood With Food

    NCT05498701 · start 2022-09-29

    Registered record
    Registry ID
    NCT05498701
    Conditions
    Healthy
    Interventions
    Tafamidis free acid tablet (Test); Tafamidis meglumine capsule (Reference)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-09-29
    Completion
    2022-12-19
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTafamidis free acid tablet (Test); Tafamidis meglumine capsule (Reference)
    PhasePhase 1
    Registry statusCompleted

  • A Study to Compare Two Tablet Forms of Tafamidis in Healthy Participants

    NCT05482308 · start 2022-08-29

    Registered record
    Registry ID
    NCT05482308
    Conditions
    Healthy
    Interventions
    Tafamidis free acid tablet (Test); Tafamidis free acid tablet (Reference)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-08-29
    Completion
    2022-10-28
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTafamidis free acid tablet (Test); Tafamidis free acid tablet (Reference)
    PhasePhase 1
    Registry statusCompleted